FDA Inspection 1322984 — Madrigal Pharmaceutical, Inc
The FDA completed an inspection of Madrigal Pharmaceutical, Inc on May 8, 2026 in Conshohocken, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- May 8, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Conshohocken, PA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)